Chronic cyclooxygenase-2 inhibition does not alter blood pressure and kidney function in renovascular hypertensive rats

Journal of Hypertension

Volumn 22, Issue 1, 2004, Pages 191-198

  Richter, Claus M ^a   Godes, Michael ^a   Wagner, Charlotte ^b   Maser Gluth, Christiane ^c   Herzfeld, Sophia ^a   Dorn, Maren ^a   Priem, Friedrich ^a   Slowinski, Torsten ^a   Bauer, Christian ^d   Schneider, Wolfgang ^e   Neumayer, Hans H ^a   Kurtz, Armin ^b   Hocher, Berthold ^a,f  

^a HUMBOLDT UNIVERSITY   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d FREIE UNIVERSITÄT BERLIN   (Germany)

^e HELIOS KLINIKUM BERLIN BUCH   (Germany)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

2K1C; Aldosterone; Celecoxib; COX 2; Cyclooxygenase 2; Inhibition; Rat; Renovascular hypertension; Therapy; Two kidney one clip

Indexed keywords

ALDOSTERONE; CELECOXIB; CREATININE; CYCLOOXYGENASE 2; PROSTAGLANDIN; RENIN; SODIUM; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; ENZYME INHIBITION; GLOMERULUS FILTRATION RATE; KIDNEY FUNCTION; MACULA DENSA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; RAT; RENOVASCULAR HYPERTENSION;

EID: 10744228024     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200401000-00029     Document Type: Article

References (33)

1. Harris RC Jr. Cyclooxygenase-2 inhibition and renal physiology. Am J Cardiol 2002; 89:10D-17D.
2. Greenberg SG, Lorenz JN, He XR, Schnermann JB, Briggs JP. Effect of prostaglandin synthesis inhibition on macula densa-stimulated renin secretion. Am J Physiol 1993; 265:F578-583.
3. Jackson EK, Oates JA, Branch RA. Indomethacin decreases arterial blood pressure and plasma renin activity in rats with aortic ligation. Circ Res 1981; 49:180-185.
4. Wang JL, Cheng HF, Harris RC. Cyclooxygenase-2 inhibition decreases renin content and lowers blood pressure in a model of renovascular hypertension. Hypertension 1999; 34:96-101.
5. Mann B, Hartner A, Jensen BL, Hilgers KF, Hocherl K, Kramer BK, Kurtz A. Acute upregulation of COX-2 by renal artery stenosis. Am J Physiol Renal Physiol 2001; 280:F119-125.
6. Goldblatt H, Lynch J, Hanzal RF, Summerville WW. Studies on experimental hypertension, I: the production of persistent elevation of systolic blood pressure by means of renal ischemia. J Exp Med 1934; 59: 347-378.
7. Pleissner KP, Regitz-Zagrosek V, Krudewagen B, Trenkner J, Hocher B, Fleck E. Effects of renovascular hypertension on myocardial protein patterns: analysis by computer-assisted two-dimensional gel electrophoresis. Electrophoresis 1998; 19:2043-2050.
8. Guirguis MS, Sattari S, Jamali F. Pharmacokinetics of celecoxib in the presence and absence of interferon-induced acute inflammation in the rat: application of a novel HPLC assay. J Pharm Sci 2001; 4:1-6.
9. Waldner C, Heise G, Meyer-Kirchrath J, Schror K, Grabensee B, Heering P. Selective cyclooxygenase-2 inhibition upregulates renal cortical alpha V integrin expression. Nephron Exp Nephrol 2003; 93:e72.
10. Hocherl K, Wolf K, Castrop H, Ittner KP, Bucher M, Kees F, Grobecker HF, Kurtz A. Renocortical expression of renin and of cyclooxygenase-2 in response to angiotensin II AT1 receptor blockade is closely coordinated but not causally linked. Pflugers Arch 2001; 442:821-827.
11. Kitahara M, Eitner F, Ostendorf T, Kunter U, Janssen U, Westenfeld R, et al. Selective cyclooxygenase-2 inhibition impairs glomerular capillary healing in experimental glomerulonephritis. J Am Soc Nephrol 2002; 13:1261-1270.
12. Hocher B, George I, Diekmann F, Zart R, Rebstock J, Schwarz A, et al. ETA receptor blockade induces fibrosis of the clipped kidney in two-kidney-one-clip renovascular hypertensive rats. J Hypertens 2000; 18:1807-1814.
13. Hocher B, George I, Rebstock J, Bauch A, Schwarz A, Neumayer HH, Bauer C. Endothelin system-dependent cardiac remodeling in renovascular hypertension. Hypertension 1999; 33:816-822.
14. Hocher B, Thone-Reineke C, Rohmeiss P, Schmager F, Slowinski T, Burst V, et al. Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension. J Clin Invest 1997; 99:1380-1389.
15. Holmer S, Rinne B, Eckardt KU, Le Hir M, Schricker K, Kaissling B, et al. Role of renal nerves for the expression of renin in adult rat kidney. Am J Physiol 1994; 266:F738-745.
16. Maser-Gluth C, Reincke M, Allolio B, Schulze E. Metabolism of glucocorticoids and mineralocorticoids in patients with adrenal incidentalomas. Eue J Clin Invest 2000; 30(suppl 3):83-86.
17. Swan SK, Rudy DW, Lasseter KC, Ryan CF, Buechel KL, Lambrecht LJ, et al. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial. Ann Intern Med 2000; 133:1-9.
18. Brater DC, Harris C, Redfem JS, Gertz BJ. Renal effects of COX-2-selective inhibitors. Am J Nephrol 2001; 21:1-15.
19. Roig F, Llinas MT, Lopez R, Salazar FJ. Role of cyclooxygenase-2 in the prolonged regulation of renal function. Hypertension 2002; 40:721-728.
20. 2 biosynthesis and renin release in the conscious dog. J Pharmacol Exp Ther 1982; 222: 410-413.
21. Hocherl K, Endemann D, Kammerl MC, Grobecker HF, Kurtz A. Cyclooxygenase-2 inhibition increases blood pressure in rats. Br J Pharmacol 2002; 136:1117-1126.
22. Kammerl MC, Nusing RM, Seyberth HW, Riegger GA, Kurtz A, Kramer BK. Inhibition of cyclooxygenase-2 attenuates urinary prostanoid excretion without affecting renal renin expression. Pflugers Arch 2001; 442: 842-847.
23. Hebert RL, Breyer RM, Jacobson HR, Breyer MD. Functional and molecular aspects of prostaglandin E receptors in the cortical collecting duct. Can J Physiol Pharmacol 1995; 73:172-179.
24. Harris RC, Breyer MD. Physiological regulation of cyclooxygenase-2 in the kidney. Am J Physiol Renal Physiol 2001; 281:F1-11.
25. Khan KN, Paulson SK, Verburg KM, Lefkowith JB, Maziasz TJ. Pharmacology of cyclooxygenase-2 inhibition in the kidney. Kidney Int 2002; 61:1210-1219.
26. Vio CP, Cespedes C, Gallardo P, Masferrer JL. Renal identification of cyclooxygenase-2 in a subset of thick ascending limb cells. Hypertension 1997; 30:687-692.
27. Breyer MD, Breyer RM. Prostaglandin receptors: their role in regulating renal function. Curr Opin Nephrol Hypertens 2000; 9:23-29.
28. Eng E, Veniant M, Floege J, Fingerle J, Alpers CE, Menard J, et al. Renal proliferative and phenotypic changes in rats with two-kidney, one-clip Goldblatt hypertension. Am J Hypertens 1994; 7:177-185.
29. Zoja C, Benigni A, Noris M, Corna D, Casiraghi F, Pagnoncelli M, et al. Mycophenolate mofetil combined with a cyclooxygenase-2 inhibitor ameliorates murine lupus nephritis. Kidney Int 2001; 60:653-663.
30. Patrono C, Ciabattoni G, Remuzzi G, Gotti E, Bombardieri S, Di Munno O, et al. Functional significance of renal prostacyclin and thromboxane A2 production in patients with systemic lupus erythematosus. J Clin Invest 1985; 76:1011-1018.
31. Kelley VE, Sneve S, Musinski S. Increased renal thromboxane production in murine lupus nephritis. J Clin Invest 1986; 77:252-259.
32. Coffman TM, Spurney RF, Mannon RB, Levenson R. Thromboxane A2 modulates the fibrinolytic system in glomerular mesangial cells. Am J Physiol 1998; 275:F262-269.
33. Miyajima A, Ito K, Asano T, Seta K, Ueda A, Hayakawa M. Does cyclooxygenase-2 inhibitor prevent renal tissue damage in unilateral ureteral obstruction? J Urol 2001; 166:1124-1129.